drugset / Trial / NCT05376644
Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3
Completed
15 enrolled
Tomsk National Research Medical Center of the Russian Academy of Sciences
Uppsala University · collab
NaSingle-groupOpen-labelDiagnostic
Summary
An open-label, single center study with 99mTc-ADAPT6 and 99mTc-DARPinG3 SPECT and biopsies of primary tumour in HER2-positive Breast Cancer before system (chemo/targeted) therapy, where the primary endpoint of the study is to compare imaging properties of 99mTc-ADAPT6 and 99mTc-DARPin G3 SPECT in HER2-positive breast cancer patients.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2022-12-31
- Completion
- 2023-01-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 99mTc-ADAPT6 | Unknown | — | — |
| Subject | 99mTc-DARPinG3 | Unknown | — | — |